A new study conducted by the American Academy of Neurology found CBD decreased atonic seizures (commonly known as "drop" seizures) by as much as 50% in patients suffering from a specific and severe form of epilepsy known as Lennox-Gastaut Syndrome (LGS). The study involved 225 participants with LGS who experienced an average of 85 atonic seizures per month and who had tried an average of six epilepsy medications without finding relief. During the study, each patient also took an average of three epilepsy medications. The patients were divided into three groups, in which one group was given 20 mg per kg of body weight, while another received 10 mg/kg, and the last group received placebo.
Of the first group, 42% saw a reduction in atonic seizures, with 40% of them saying their seizures were cut in half. Of the second group, 37% experienced a reduction, with 36% of them saying their seizures were cut in half. The placebo group experienced a 17% reduction in atonic seizures, with 15% saying their seizures were cut in half. While side effects were reported, they were mild and consisted of drowsiness and a limited appetite. All in all, those who took CBD treatment were 2.6 times more likely to report an improvement in their conditions.
Author of the study Anup Patel, MD, of Nationwide Children's Hospital and the Ohio State University College of Medicine, explains, “Our results suggest that cannabidiol may be effective for those with Lennox-Gastaut syndrome in treating drop seizures... This is important because this kind of epilepsy is incredibly difficult to treat. While there were more side effects for those taking cannabidiol, they were mostly well-tolerated. I believe that it may become an important new treatment option for these patients.”
This information has been provided by MassRoots and approved by our Chief Medical Officer.